🔬🧬 Oncology Updates: TG4050 Vaccine Progress, EGFR NSCLC Trial Completion, and Global Approvals in Breast, Lung, and Prostate Cancers
From head and neck cancer immunotherapy milestones to HER2 lung cancer grants and next-gen prostate cancer trials—this week’s oncology roundup delivers essential breakthroughs shaping the future of solid tumor treatment.
💡 Key Highlights This Week:
✅ Transgene completes Phase II screening for TG4050 in HPV-negative head and neck cancer with Phase I showing 100% disease-free survival at 2 years
✅ Dizal wraps enrollment in global Phase III trial for EGFR exon 20 insertion NSCLC; prior data shows 78.6% ORR and 12.4-month median PFS
🧬 Boehringer Ingelheim and LCRF launch $2.25M research initiative focused on HER2-mutant NSCLC biology and therapy development
🇬🇧 Serplulimab approved in the UK as first anti-PD-1 therapy for extensive-stage small cell lung cancer, with survival extended to 15.4 months
🍁 Health Canada approves KISQALI for early HR+/HER2- breast cancer based on 25.1% iDFS risk reduction in NATALEE trial
🧪 ZetaMast reduces tumor volume 4-fold and boosts survival 3.9x in TNBC liver metastases mouse model; Phase Ib set for 2026
🧬 Medicovestor’s ADoBind MC001 receives FDA Orphan Drug Designation for pancreatic cancer; Phase 1 planned for early 2026
🇪🇺 CABOMETYX recommended by CHMP for advanced pNET and epNET based on Phase III CABINET trial
🧔 Bayer’s Darolutamide gains CHMP support for metastatic hormone-sensitive prostate cancer, reducing risk of progression/death by 46%
💉 Daiichi Sankyo and Merck launch 1,440-patient global Phase III trial for B7-H3 ADC ifinatamab deruxtecan in mCRPC
⚛️ Archeus receives FDA IND for ART-101, a PSMA-targeted radiopharmaceutical with superior tumor targeting and fewer off-target effects
🎯 Whether you’re following immunotherapy, targeted radiopharmaceuticals, or next-gen antibody-drug conjugates—this video gives you the essential insights to stay informed and ahead.
📢 Stay Ahead in Oncology Research!
✅ Like, share, and subscribe for weekly updates on oncology breakthroughs and solid tumor therapies
#Oncology #CancerResearch #TG4050 #NSCLC #BreastCancer #ProstateCancer #LungCancer #TNBC #HER2 #Immunotherapy #Radiopharmaceuticals #AntibodyDrugConjugate #ClinicalTrials #LucidQuest #PharmaNews #HealthcareInnovation #OncologyUpdates #BiotechNews #SolidTumors